Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03350529 (Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer), which is not on this map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries.World journal of urology · 2021Pooled it
- A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?World journal of urology · 2019Pooled it
- Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.Prostate cancer and prostatic diseases · 2015Trial
- PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review.European urology open science · 2026Review
- Comparison of Complications and Mid-term Results for Patients who Underwent Open Radical Prostatectomy for High-Risk and Oligometastatic Prostate Cancer: A Cross-Sectional Study from a Tertiary Reference Center.Annals of surgical oncology · 2024Article
- [Local therapies for oligometastatic hormone-sensitive prostate cancer].Urologie (Heidelberg, Germany) · 2024Review
- A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients.Clinical and translational medicine · 2024Article
- The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: A population-based study.Cancer medicine · 2023Article
- Oligometastatic Prostate Cancer: Is there a Role for Surgery? A Narrative Review.Turkish journal of urology · 2022Article
- Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer.Asian journal of urology · 2022Article
- Article
- Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.BMC cancer · 2020Article
- Cytoreductive treatment strategies for de novo metastatic prostate cancer.Nature reviews. Clinical oncology · 2020Review
- Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer.Frontiers in oncology · 2020Article
- Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.International journal of urology : official journal of the Japanese Urological Association · 2018Article
- Emerging role of cytoreductive prostatectomy in patients with metastatic disease.Translational andrology and urology · 2018Review
- p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer.Cell death & disease · 2018Article
- Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary.Current urology reports · 2017Review
- A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.Urology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
purposeClinicians are increasingly willing to treat prostate cancer within the primary site in the presence of regional lymph node or even limited distant metastases. However, no formal study on the merits of this approach has been reported. We used a preoperative clinical discovery platform to prioritize pathways for assessment as therapeutic targets and to test the hypothesis that the primary site harbors potentially lethal tumors after aggressive treatment. PATIENTS AND
methodsPatients with locally advanced or lymph node-metastatic prostate cancer underwent 1 year of androgen ablation and three cycles of docetaxel therapy, followed by prostatectomy. All specimens were characterized for stage by accepted criteria. Expression of select molecular markers implicated in disease progression and therapy resistance was determined immunohistochemically and compared with that in 30 archived specimens from untreated patients with high-grade prostate cancer. Marker expression was divided into three groups: intracellular signaling pathways, stromal-epithelial interaction pathways, and angiogenesis.
resultsForty patients were enrolled, 30 (75%) of whom underwent prostatectomy and two (5%) who underwent cystoprostatectomy. Twenty-nine specimens contained sufficient residual tumor for inclusion in a tissue microarray. Immunohistochemical analysis showed increased epithelial and stromal expression of CYP17, SRD5A1, and Hedgehog pathway components, and modulations of the insulin-like growth factor I pathway.
conclusionA network of molecular pathways reportedly linked to prostate cancer progression is activated after 1 year of therapy; biomarker expression suggests that potentially lethal cancers persist in the primary tumor and may contribute to progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.